Viral vectors

Details Viral vectors Viral vectors

2011-07-19

2011-07-19

Li, Bao (Department: 1648)

Chemistry: molecular biology and microbiology

Vector, per se

C435S235100, C435S091400, C424S093200

Reexamination Certificate

active

07981669

ABSTRACT:
The present invention provides a herpes virus which lacks a functional ICP34.5 encoding gene and which comprises two or more of—(i) a gene encoding a prodrug converting enzyme; (ii) a gene encoding a protein capable of causing cell to cell fusion; and (iii) a gene encoding an immunomodulatory protein.

REFERENCES:
patent: 5328688 (1994-07-01), Roizman
patent: 5585096 (1996-12-01), Martuza et al.
patent: 5824318 (1998-10-01), Mohr et al.
patent: 5876923 (1999-03-01), Leopardi et al.
patent: 6248320 (2001-06-01), Coffin et al.
patent: 6284289 (2001-09-01), Van den Berghe
patent: 6428968 (2002-08-01), Molnar-Kimber et al.
patent: 6641817 (2003-11-01), Coffin et al.
patent: 6713067 (2004-03-01), Coffin
patent: 6719982 (2004-04-01), Coffin et al.
patent: 6821753 (2004-11-01), Coffin
patent: 7063835 (2006-06-01), Coffin et al.
patent: 7118755 (2006-10-01), Coffin et al.
patent: 7223593 (2007-05-01), Coffin et al.
patent: 7537924 (2009-05-01), Coffin
patent: 2003/0040500 (2003-02-01), Coffin
patent: 2003/0044384 (2003-03-01), Roberts et al.
patent: 2003/0091537 (2003-05-01), Coffin
patent: 2003/0113348 (2003-06-01), Coffin
patent: 2003/0219409 (2003-11-01), Coffin et al.
patent: 2004/0022812 (2004-02-01), Coffin
patent: 2004/0063094 (2004-04-01), Coffin et al.
patent: 2004/0219167 (2004-11-01), Coffin
patent: 2005/0249707 (2005-11-01), Coffin et al.
patent: 2006/0121522 (2006-06-01), Coffin
patent: 2006/0188480 (2006-08-01), Coffin et al.
patent: 2007/0003571 (2007-01-01), Coffin
patent: 2007/0264282 (2007-11-01), Coffin
patent: 0828005 (1998-03-01), None
patent: 92/13943 (1992-08-01), None
patent: WO-96/16164 (1996-05-01), None
patent: WO-97/04804 (1997-02-01), None
patent: 97/20935 (1997-06-01), None
patent: WO-97/26904 (1997-07-01), None
patent: WO-98/04726 (1998-02-01), None
patent: WO-98/30707 (1998-07-01), None
patent: WO-98/37905 (1998-09-01), None
patent: WO-98/40492 (1998-09-01), None
patent: WO-98/42855 (1998-10-01), None
patent: WO-98/51809 (1998-11-01), None
patent: WO-99/06583 (1999-02-01), None
patent: WO-99/38955 (1999-08-01), None
patent: WO-99/60145 (1999-11-01), None
patent: WO-00/08191 (2000-02-01), None
patent: WO-00/08194 (2000-02-01), None
patent: WO-00/40734 (2000-07-01), None
patent: WO-00/75292 (2000-12-01), None
patent: WO-01/46449 (2001-06-01), None
patent: WO-01/46450 (2001-06-01), None
patent: WO-01/53505 (2001-07-01), None
patent: WO-01/53506 (2001-07-01), None
patent: WO-01/53506 (2001-07-01), None
patent: WO-01/53507 (2001-07-01), None
patent: WO-01/77358 (2001-10-01), None
patent: WO-2005/011715 (2005-02-01), None
Liu et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy, Feb. 2003, vol. 10, No. 4, pp. 292-303.
Moriuchi et al. Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Therapy, May 2002, vol. 9, No. 9, pp. 584-591.
Galanis et al. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Human Gene Therapy, May 2001, vol. 12, No. 7, pp. 811-821.
Jones et al. Mutational Analysis of the herpes simplex virus virus virions host shutoff protein; evidence that vhs functions in the absence of other viral proteins. Journal of Virology, Aug. 1995, vol. 69, No. 8, pp. 4862-4871.
Cassady et al. Journal of Virology, Nov. 1998, vol. 72, No. 11, pp. 8620-8626. especially Abstract.
Varghese et al. Cancer Gene Therapy, Dec. 2002, vol. 9, No. 12, pp. 967-978.
International Search Report for PCT International No. PCT/GB2004/003217.
Fu, Xinping, et al.; Expression of a Fusogenic Membrane Glycoprotein by an Oncolytic Herpes Simplex Virus Potentiates the Viral Antitumor Effect; Molecular Therapy 7(6):748-754, Jun. 2003.
Andreansky et al., “Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors,”Cancer Res., 57(8): 1502-1509, 1997.
Andreansky et al., “The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors,”Proc. Nat. Acad. Sci. USA, 93: 11313-11318, 1996.
Andreansky et al., “Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins,”Gene Therapy, 5: 121-130, 1998.
Bateman et al., “Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth,”Cancer Res., 60: 1492-1497, 2000.
Broberg et al., “Expression of interleukin-4 but not of interleukin-10 form a replicative herpes simplex virus type 1 viral vector precludes experimental allergic encephalomyelitis,”Gene Therapy, 8: 769-777, 2001.
Bronte et al., “IL-2 enhances the function of recombination poxvirus-based vaccines in the treatment of established pulmonary metastases,”J. Immunol., 154: 5282-5292, 1995.
Chambers et al., “Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in ascidmouse model of human malignant glioma,”Proc. Natl. Acad. Sci. USA, 92(5): 1411-1415, 1995.
Chou et al., “Mapping of herpes simplex virus-1 neurovirulence to γ34.5, a gene nonessential for growth in culture,”Science, 250: 1262-1266, 1990.
Coukos et al., “Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53 independent death and is efficacious against chemotherapy-resistant ovarian cancer,”Clin. Cancer Res., 6: 3342-3353, 2000.
Coukos et al., “Producer cells enhance the oncolytic effect of a replication-competent ICP34.5-null herpes simplex virus-1 (HSV-1) strain in epithelial ovarian cancer,”Cancer Gene Ther., 5(6): S7, 1998.
Coukos et al., “Use of carrier cells to deliver a replication selective herpes simplex virus-1 mutant for the intrapetioneal therapy of epithelial ovarian cancer,”Clin. Cancer Res., 5: 1523-1537, 1999.
Dranoff et al., “Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity,”Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
Ejercito et al., “Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells,”J. Gen. Virol., 2: 357-364, 1968.
Ezzeddine et al., “Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene,”The New Biologist, 3(6): 608-614, 1991.
Fulci et al., “Oncolytic viruses for the therapy of brain tumors and other solid malignancies: a review,”Frontiers in Bioscience, 8: e346-360, 2003.
Galanis et al., “Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas,”Human Gene Therapy, 12: 811-821, 2001.
Goldsmith et al., “Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response,”J. Exp. Med., 187(3): 341-348, 1998.
Gossen et al., “Tight control of gene expression in mammalian cells by tetracycline-repsonsive promoters,”Proc. Natl. Acad. Sci. USA, 89: 5547-5551, 1992.
Gossen et al., “Transcriptional activation by tetracyclines in mammalian cells,”Science, 268: 1766-1769, 1995.
He et al., “Suppression of the phenotype ofγ134.5 herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the α47 gene,”J. Virology, 71(8): 6049-6054, 1997.
Hill et al., “Herpes simplex virus turns off the TAP to evade host immunity,”Nature, 375: 411-415, 1995.
Hunter et al., “Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates,”J. Virol., 73(8): 6319-6326, 1999.
Irvine et al., “Cytokine enhancement of DNA immuniza

Affiliated with

Also associated with

Rating

Viral vectors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Viral vectors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral vectors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2727292